Malignant neoplasm of breast
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
mRNA and protein expression of PGC-1β and FOXA2 in breast cancer tissues and cell lines were determined by qRT-PCR and Western Blotting, respectively.
|
31007610 |
2019 |
Breast Carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
mRNA and protein expression of PGC-1β and FOXA2 in breast cancer tissues and cell lines were determined by qRT-PCR and Western Blotting, respectively.
|
31007610 |
2019 |
Malignant neoplasm of breast
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Using quantitative PCR and immunoblotting, we showed that breast cancer cells with HER2-amplification (SKBR-3) have greater expression of PGC-1β as compared to a non-tumorous breast cell (MCF-10A) and higher proliferation rate.
|
26602383 |
2016 |
Malignant neoplasm of breast
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
To evaluate whether the presence of polymorphisms of peroxisome proliferator-activated receptor gamma PPARγ (Pro 1 2Ala) and PPARGC1B (Ala203Pro) modifies the association between the inorganic arsenic (iAs) methylation capacity and breast cancer (BC).
|
27557380 |
2016 |
Breast Carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Using quantitative PCR and immunoblotting, we showed that breast cancer cells with HER2-amplification (SKBR-3) have greater expression of PGC-1β as compared to a non-tumorous breast cell (MCF-10A) and higher proliferation rate.
|
26602383 |
2016 |
Breast Carcinoma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
To evaluate whether the presence of polymorphisms of peroxisome proliferator-activated receptor gamma PPARγ (Pro 1 2Ala) and PPARGC1B (Ala203Pro) modifies the association between the inorganic arsenic (iAs) methylation capacity and breast cancer (BC).
|
27557380 |
2016 |
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
Apoptosis induced by PGC-1β in breast cancer cells is mediated by the mTOR pathway.
|
23877360 |
2013 |
Malignant neoplasm of breast
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
PPARγ and PPARGC1B polymorphisms modulate the association between phthalate exposure and BC risk.
|
23866026 |
2013 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
Apoptosis induced by PGC-1β in breast cancer cells is mediated by the mTOR pathway.
|
23877360 |
2013 |
Breast Carcinoma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
PPARγ and PPARGC1B polymorphisms modulate the association between phthalate exposure and BC risk.
|
23866026 |
2013 |
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
PGC-1β knockdown in breast cancer cells impaired ERRα signaling and reduced cell proliferation, implicating a functional role for PGC-1β/ERRα in the pathogenesis of breast cancers.
|
22014575 |
2011 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
PGC-1β knockdown in breast cancer cells impaired ERRα signaling and reduced cell proliferation, implicating a functional role for PGC-1β/ERRα in the pathogenesis of breast cancers.
|
22014575 |
2011 |
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
CTD_human |
Taken together, our results suggest that ERRα and PGC-1β are key players in the etiology of malignant breast cancer by coordinating the transcriptional regulation of genes located in the 17q12 region, a process that also involves interference with the repressive function of ERα on ERBB2 expression.
|
20961995 |
2010 |
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that ERRα and PGC-1β are key players in the etiology of malignant breast cancer by coordinating the transcriptional regulation of genes located in the 17q12 region, a process that also involves interference with the repressive function of ERα on ERBB2 expression.
|
20961995 |
2010 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that ERRα and PGC-1β are key players in the etiology of malignant breast cancer by coordinating the transcriptional regulation of genes located in the 17q12 region, a process that also involves interference with the repressive function of ERα on ERBB2 expression.
|
20961995 |
2010 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
CTD_human |
Taken together, our results suggest that ERRα and PGC-1β are key players in the etiology of malignant breast cancer by coordinating the transcriptional regulation of genes located in the 17q12 region, a process that also involves interference with the repressive function of ERα on ERBB2 expression.
|
20961995 |
2010 |
Malignant neoplasm of breast
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
The genotype-combination analysis of the associated PPARGC1A Thr612Met variant and the associated PPARGC1B Ala203Pro variant suggests an allele dose-dependent breast cancer risk (P(trend) = 0.0004).
|
16704985 |
2006 |
Breast Carcinoma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
The genotype-combination analysis of the associated PPARGC1A Thr612Met variant and the associated PPARGC1B Ala203Pro variant suggests an allele dose-dependent breast cancer risk (P(trend) = 0.0004).
|
16704985 |
2006 |
Malignant neoplasm of breast
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
We conclude that there is aberrant expression of PPARgamma and its co-activator, PGC-1, in human breast cancer and low levels of these molecules in cancer tissues are associated with poor clinical outcomes.
|
12866036 |
2003 |
Breast Carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
We conclude that there is aberrant expression of PPARgamma and its co-activator, PGC-1, in human breast cancer and low levels of these molecules in cancer tissues are associated with poor clinical outcomes.
|
12866036 |
2003 |
Obesity
|
0.370 |
Biomarker
|
disease |
CTD_human |
Mitochondrial-related gene associated to obesity can be modulated by in utero hyperglycemic environment.
|
30738174 |
2019 |
Obesity
|
0.370 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to determine the possible association of five single-nucleotide polymorphisms (SNPs) located in the IGF2, LEPR, POMC, PPARG, and PPARGC1 genes with obesity or obesity-related risk phenotypes.
|
25923461 |
2015 |
Obesity
|
0.370 |
Biomarker
|
disease |
BEFREE |
In this review, we outline the function of PGC-1 coactivators in physiological and pathological conditions as well as the complex interplay of metabolic dysregulation and inflammation in obesity with special focus on skeletal muscle.
|
24258516 |
2014 |
Obesity
|
0.370 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma co-activator 1beta (PPARGC1B) may play an important role in obesity and Type 2 diabetes mellitus (T2DM).
|
16759305 |
2006 |
Obesity
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
We studied variation in the coding region of human PPARGC1B in Danish whites and related these variations to the prevalence of obesity and type 2 diabetes in population based samples.
|
15863669 |
2005 |